TD Cowen Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $160

Futu News19:31 · Ratings

Ascendis Pharma Ticks Higher Amid Report It Cancelled From Upcoming Conference

Seeking AlphaOct 17 00:11

MBX Bio Drops Despite Bullish Views on Street

Seeking AlphaOct 9 03:15

Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167

Futu NewsOct 7 21:34 · Ratings

Septerna, Hypoparathyroidism Drug Developer, Files for $100M IPO

Seeking AlphaOct 4 01:36

Ascendis Pharma Submits Supplemental Biologics License Application for Pediatric Growth Hormone Drug

MT NewswiresSep 30 21:23